Bruce A W, Reid G
Department of Surgery, Toronto General Hospital, Ont., Canada.
Can J Microbiol. 1988 Mar;34(3):339-43. doi: 10.1139/m88-062.
Urinary tract infections remain a common problem, particularly in the female population. New methods are required to manage recurrent cystitis, and extensive research to date has suggested that restoration of the lactobacilli flora of the urogenital tract may prevent these infections. In this study, five females suffering from recurrent urinary tract infections were treated twice weekly with intravaginal and perineal implantation of Lactobacillus casei GR-1. These organisms colonized the epithelium and prevented the emergence of coliform bacteria in most instances, but did not appear to affect enterococcal colonization. In vitro studies showed that L. casei GR-1 inhibited the growth of the coliforms but did not inhibit enterococci. Each of the five patients had infection-free periods ranging from 4 weeks to 6 months. The treatment was well tolerated, had no side effects, led to an improved well-being, and was preferred to antibiotic treatment by all of the patients. These human studies, albeit of a limited nature, are the first to examine the potential for lactobacillus therapy in the prevention of urinary tract infections. The results show that lactobacilli therapy, using carefully selected organisms to treat patients who are closely followed, may be effective in the prevention of recurrent urinary tract infections.
尿路感染仍然是一个常见问题，尤其是在女性群体中。需要新的方法来治疗复发性膀胱炎，而迄今为止的大量研究表明，恢复泌尿生殖道的乳酸杆菌菌群可能预防这些感染。在本研究中，五名患有复发性尿路感染的女性每周接受两次阴道和会阴植入干酪乳杆菌GR-1的治疗。这些微生物在大多数情况下定殖于上皮细胞并阻止了大肠菌的出现，但似乎并未影响肠球菌的定殖。体外研究表明，干酪乳杆菌GR-1抑制大肠菌的生长，但不抑制肠球菌。五名患者每人都有4周至6个月的无感染期。该治疗耐受性良好，无副作用，使健康状况得到改善，且所有患者都更倾向于这种治疗而非抗生素治疗。这些人体研究虽然规模有限，但却是首次研究乳酸杆菌疗法预防尿路感染的潜力。结果表明，使用精心挑选的微生物对密切随访的患者进行乳酸杆菌治疗，可能对预防复发性尿路感染有效。
